



## Protocol Review and Monitoring System – Protocol or Concept Submission Form

Appendix 8.3 Form only See SOP 2.1 Attachment A for completion instructions.

Please complete all fields and save the form as a separate word document or PDF. No alterations to requirements may be made. Incomplete forms will be returned. Submission will not proceed to review until all information is complete. Please submit the completed form to: [humansubjectsresearch@cc.hawaii.edu](mailto:humansubjectsresearch@cc.hawaii.edu) . Please include Protocol/Study, ICF if applicable and Data Safety Monitoring Plan if separate from Protocol/Study. This form is also available as a fillable PDF (Appendix 8.3), please contact the Clinical Trials Office for assistance.

Form Completed by: \_\_\_\_\_ Date: \_\_\_\_\_

This is a protocol submission for review and approval Yes \_\_\_ or No \_\_\_

This is a concept submission for feedback from the CRAB/PRMC only Yes \_\_\_ No \_\_\_

Study Funded? Yes \_\_\_ No \_\_\_ If yes source:

Non Funded studies/Studies awaiting funding are only eligible for concept review. Unless there is a requirement for IRB approval prior to funding. If so, please document requirement:

---

---

---

1. Title of Protocol or Concept:

2. Short Title:

3. Objectives:

Includes Adults \_\_\_\_\_ Children (<18y/o) \_\_\_\_\_ or both: \_\_\_\_\_

4. Sponsor /Group and Protocol Number:

5. Primary Purpose:

6. Phase: I \_\_\_ I/II \_\_\_ II \_\_\_ II/III \_\_\_ III \_\_\_ III/IV \_\_\_ IV \_\_\_ Pilot \_\_\_ N/A \_\_\_

Other please specify: \_\_\_\_\_



**Observational** \_\_\_\_ or **Interventional** \_\_\_\_

**Ancillary** \_\_\_\_ or **Correlative** \_\_\_\_ or **Both** \_\_\_\_

**Cancer Primary Site:** \_\_\_\_\_

7. **Scope:** Local \_\_\_\_ or National \_\_\_\_

8. **Investigator Initiated Protocol:** Yes \_\_\_\_ or No \_\_\_\_

9. **NCI Designated as Cancer Control (please review definition in instructions):**

Yes \_\_\_\_ or No \_\_\_\_

10. **Principal Investigator Name:**

**Email:**

**Phone:**

11. **Study Contact/Coordinator Name:**

**Email:**

**Phone:**

12. **Sub-Investigators (list all):**

13. **Has this protocol or concept had a national peer review?** Yes \_\_\_\_ or No \_\_\_\_

**If yes when and where** \_\_\_\_\_ **(please include copies of the reviews).**

14. **Target enrollment for study:** \_\_\_\_\_ **Anticipated enrollment: locally** \_\_\_\_\_

15. **Anticipated study start date:** \_\_\_\_\_ **Anticipated study end date:** \_\_\_\_\_

16. **Investigational Drug:** Yes \_\_\_\_ or No \_\_\_\_ **If Yes IND Holder:** \_\_\_\_\_

**IND #:** \_\_\_\_\_

17. **NCT #:** \_\_\_\_\_

18. **Would you like Cancer Center Clinical Translational Research Services regulatory support for this trial?** Yes \_\_\_\_ or No \_\_\_\_ (Investigators not utilizing CTO support will be responsible for maintaining all regulatory documents in OnCore CTMS).



19. Is this a multisite trial? Yes \_\_\_ or No \_\_\_

List Local sites anticipated to enroll subjects:

20. What other, if any, local studies are open for similar group of patients that may be competing with this study? List:

21. Is this a rare cancer? Yes \_\_\_ or No \_\_\_

22. Does this study involve drug accountability? Yes \_\_\_ or No \_\_\_

Investigational Drug? Yes \_\_\_ or No \_\_\_

23. Does this study involve therapy? Yes \_\_\_ or No \_\_\_

24. Does the study include specimen banking? Yes \_\_\_ or No \_\_\_

25. Does the study involve an investigational device? Yes \_\_\_ or No \_\_\_

26. Does the study involve adjuvant treatment? Yes \_\_\_ or No \_\_\_

27. Data Safety Monitoring provided by: PI \_\_\_ or UH CC \_\_\_ DSMC \_\_\_ or External \_\_\_.

28. Anticipated study start (accrual) date: \_\_\_\_\_

29. Anticipated study completion date: \_\_\_\_\_

Please provide a justification to open the study at UH Cancer Center/Consortium Member Site/Local Provider (e.g., reason to open, programmatic strategy, good use of available time and resources, patient need, etc. not otherwise documented on this form or within the Protocol/Concept).



Do all research staff have access to OnCore® Clinical Trial Management System: (staff access will be set based on this information): Yes \_\_\_\_\_ or No \_\_\_\_\_

If no, please request staff to request OnCore access from UH Cancer Center Clinical Trials Office via email at [oncore@cc.hawaii.edu](mailto:oncore@cc.hawaii.edu) .

Do all research staff have current required training on file in OnCore (Human Subject Research Protection, Good Clinical Practice and HIPAA)? Yes \_\_\_ or No \_\_\_ If unsure, please contact [humansubjectsresearch@cc.hawaii.edu](mailto:humansubjectsresearch@cc.hawaii.edu) for a report.

If not on file, please forward documents with this submission for all staff. If not complete, please complete these UH required trainings prior to this submission.

**PI Signature/Designee and date:**

Valid electronic signature acceptable

**Please submit this form and a copy of the research project document (Protocol) and Informed Consent Document (if applicable) and Data Safety Monitoring Plan to [humansubjectsresearch@cc.hawaii.edu](mailto:humansubjectsresearch@cc.hawaii.edu) .**